Cytogenetic studies in patients with hemophilic hemarthrosis treated by 198Au, 186Rh, and 90Y radioactive synoviorthesis.
This study assesses chromosomal structural changes (CSCs) studied by conventional lymphocyte cultures and banding techniques in 79 hemophilic patients with hemarthrosis treated with radioactive synoviorthesis, 31 hemophilic patients with hemarthrosis not treated by this procedure, and 110 nonhemophilic patients matched by age and sex (control group). In 14 patients treated with 198Au (group A), premalignant CSCs and nonspecific CSCs were found, respectively, in 1.69% and 17.23% of metaphases. The former disappeared, but 1.7% of the nonspecific changes persisted 2 years after injection. In 31 patients treated with 186Rh (group B), CSCs were not found previous to radioactive synoviorthesis but were present as nonspecific changes in 1.25% of metaphases 6 months later; they disappeared 1 year after injection. In 34 patients treated with 90Y (group C), CSCs were not found previous to radioactive synoviorthesis but were present as nonspecific changes in 0.89% of metaphases 6 months later; they disappeared 1 year after injection. Only nonspecific CSCs were found in 0.79% of metaphases in patients not treated with radioactive synoviorthesis (group D). CSCs were not present in control subjects. The authors conclude that in some hemophilic patients with hemarthosis treated with radioactive synoviorthesis using 198Au, 186Rh, or 90Y, reversible premalignant or nonspecific CSCs could be present; nonspecific CSCs may persist in a low proportion of metaphases up to 2 years after injection when 198Au is used as the radioactive agent. Radioactive synoviorthesis seems to be from a cytogenetic point of view a safe alternative for these patients.
Falcón de Vargas
A
A
Genetics Unit, Hospital Vargas de Caracas, Venezuela.
Fernandez-Palazzi
F
F
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D006050:Gold Radioisotopes / Q000627:therapeutic use*; D006395:Hemarthrosis / Q000209:etiology / Q000235:genetics* / Q000532:radiotherapy*; D006467:Hemophilia A / Q000150:complications*; D006801:Humans; D007223:Infant; D008677:Metaphase; D011868:Radioisotopes / Q000627:therapeutic use*; D012238:Rhodium / Q000627:therapeutic use*; D013583:Synovial Membrane; D015021:Yttrium Radioisotopes / Q000627:therapeutic use*
D006050:Gold Radioisotopes; D011868:Radioisotopes; D015021:Yttrium Radioisotopes; D012238:Rhodium